While a 1-year course of methotrexate improved physical function, pain, morning joint stiffness, and joint inflammation, it did not prevent the development of clinical arthritis. Among patients with ...

Alvotech (ALVO) and Advanz Pharma on Thursday said that the European Commission has granted marketing authorizations in the ...

“As the first biosimilar to Simponi (golimumab) to gain approval in the European market, we are committed to expanding access ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA treated with first-line upadacitinib over 5 years had greater reductions in disease activity vs ...

COPENHAGEN -- Methotrexate helped high-risk individuals with aching and inflamed joints, but who didn't yet have overt rheumatoid arthritis (RA), avoid that diagnosis for close to 2 years in a ...

Combination of antiangiogenic nanotherapy and MTX leads to sustained clinical response in the K/BxN mouse model of inflammatory arthritis. On day 2 after serum transfer, when arthritis was clearly ...

The intracellular polyglutamation of methotrexate (MTX) is emerging as a crucial biochemical process in rheumatoid arthritis (RA) therapy. MTX polyglutamates (MTX-PGs) are metabolites formed by the ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Denise Johnston stood in line at the pharmacy to pick up her monthly prescription of methotrexate, which she takes to relieve pain from her psoriatic arthritis. A month earlier, Johnston, 49, picked ...

In this study, the enhancement of conventional DMARD treatment with antiangiogenic nanotherapy was demonstrated in a preclinical model of inflammatory arthritis. Although the specific mechanistic ...